Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5864 Articles

Chris Lange | Oct 30, 2015 at 10:10 AM EDT

Voyager Therapeutics Sets Terms for IPO

Voyager Therapeutics intends to offer roughly 4.7 million shares within the range of $15 to $17 apiece in an IPO…

Chris Lange | Oct 30, 2015 at 8:45 AM EDT

Is Mylan’s Topline Growth Enough for Investors?

Mylan reported better-than-expected third-quarter financial results before the markets opened on Friday.

Chris Lange | Oct 30, 2015 at 8:40 AM EDT

AbbVie Soars on Solid Earnings and Guidance

AbbVie reported better-than-expected third-quarter financial results before the markets opened on Friday.

Chris Lange | Oct 29, 2015 at 1:05 PM EDT

What to Expect From Mylan Earnings

Mylan is scheduled to release its third-quarter financial results before the markets open on Friday.

Chris Lange | Oct 29, 2015 at 12:25 PM EDT

What to Look For in AbbVie Earnings

AbbVie is expected to report its third-quarter financial results before the markets open on Friday.

Chris Lange | Oct 29, 2015 at 11:55 AM EDT

Abiomed Beats on Estimates, but Was It by Enough?

Abiomed reported better-than-expected fiscal second-quarter financial results before the markets opened on Thursday.

Chris Lange | Oct 29, 2015 at 11:40 AM EDT

Kura Oncology Gears Up for IPO With Updated Terms

Kura Oncology is offering $60 million worth of shares in its initial public offering at an expected $16 per share.

Jon C. Ogg | Oct 29, 2015 at 11:05 AM EDT

What a Combined Allergan and Pfizer Might Actually Look Like

Allergan has issued a press release that confirms some of the rumors floating in the market that it has been…

Trey Thoelcke | Oct 29, 2015 at 10:50 AM EDT

These Chinese Biotechs Are Severely Undervalued

Those who remember the bursting of the tech bubble at the turn of the millennium may have the nagging feeling…

Lee Jackson | Oct 29, 2015 at 9:35 AM EDT

6 Top Specialty Pharmaceutical Stocks to Buy With Over 100% Upside Potential

24/7 Wall St. screened the RBC specialty pharmaceutical universe and found six companies rated Outperform with over 100% upside to…

Chris Lange | Oct 28, 2015 at 4:41 PM EDT

Amgen Beats Earnings With Solid Outlook For 2015

ThinkstockAmgen Inc. (NASDAQ: AMGN) released its third quarter earnings report Wednesday after the markets closed. The biotech giant had $2.72…

Chris Lange | Oct 28, 2015 at 11:25 AM EDT

What to Expect From Amgen Earnings

Amgen is scheduled to report its third-quarter financial results after the markets close on Wednesday.

Lee Jackson | Oct 28, 2015 at 10:35 AM EDT

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

With specialty pharmaceutical stocks having the chance to move dramatically higher, three large cap leaders are RBC's favorites now.

Chris Lange | Oct 28, 2015 at 10:05 AM EDT

Boston Scientific Posts Solid Earnings Beat

Boston Scientific reported better-than-expected third-quarter financial results before the markets opened on Wednesday.

Chris Lange | Oct 27, 2015 at 4:22 PM EDT

Are Gilead Earnings Enough for Investors?

Gilead Sciences reported its third-quarter financial results after the markets closed on Tuesday.

1 … 236 237 238 239 240 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Voyager Therapeutics Sets Terms for IPO

Is Mylan’s Topline Growth Enough for Investors?

AbbVie Soars on Solid Earnings and Guidance

What to Expect From Mylan Earnings

What to Look For in AbbVie Earnings

Abiomed Beats on Estimates, but Was It by Enough?

Kura Oncology Gears Up for IPO With Updated Terms

What a Combined Allergan and Pfizer Might Actually Look Like

These Chinese Biotechs Are Severely Undervalued

6 Top Specialty Pharmaceutical Stocks to Buy With Over 100% Upside Potential

Amgen Beats Earnings With Solid Outlook For 2015

What to Expect From Amgen Earnings

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

Boston Scientific Posts Solid Earnings Beat

Are Gilead Earnings Enough for Investors?

Bitcoin Price: BTC Just Reclaimed the Bull Market Support Band for the First Time in 6 Months

ULTY’s Weekly Payouts Collapsed 80% in 2025, Now Recovering to $0.40

U.S. Navy intercepts Iranian cruise missiles — 4 defense stocks to watch today

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how

Bitcoin Price: BTC Just Reclaimed the Bull Market Support Band for the First Time in 6 Months

ULTY’s Weekly Payouts Collapsed 80% in 2025, Now Recovering to $0.40

Health and Healthcare Articles

All Health and Healthcare Articles

Voyager Therapeutics Sets Terms for IPO

Is Mylan’s Topline Growth Enough for Investors?

AbbVie Soars on Solid Earnings and Guidance

What to Expect From Mylan Earnings

What to Look For in AbbVie Earnings

Abiomed Beats on Estimates, but Was It by Enough?

Kura Oncology Gears Up for IPO With Updated Terms

What a Combined Allergan and Pfizer Might Actually Look Like

These Chinese Biotechs Are Severely Undervalued

6 Top Specialty Pharmaceutical Stocks to Buy With Over 100% Upside Potential

Amgen Beats Earnings With Solid Outlook For 2015

What to Expect From Amgen Earnings

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

Boston Scientific Posts Solid Earnings Beat

Are Gilead Earnings Enough for Investors?

Bitcoin Price: BTC Just Reclaimed the Bull Market Support Band for the First Time in 6 Months

ULTY’s Weekly Payouts Collapsed 80% in 2025, Now Recovering to $0.40

U.S. Navy intercepts Iranian cruise missiles — 4 defense stocks to watch today

Featured Reads

A Couple With $3.1 Million Disagrees on Whether to Take Social Security at 62 or 70

This health insurer lost 2 million customers — and made $1.5 Billion anyway. Here's how